BiomarCaRE
Standard
BiomarCaRE : rationale and design of the European BiomarCaRE project including 300,000 participants from 13 European countries. / Zeller, Tanja; Hughes, Maria; Tuovinen, Tarja; Schillert, Arne; Conrads-Frank, Annette; Ruijter, Hester den; Schnabel, Renate B; Kee, Frank; Salomaa, Veikko; Siebert, Uwe; Thorand, Barbara; Ziegler, Andreas; Breek, Heico; Pasterkamp, Gerard; Kuulasmaa, Kari; Koenig, Wolfgang; Blankenberg, Stefan.
In: EUR J EPIDEMIOL, Vol. 29, No. 10, 10.2014, p. 777-790.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - BiomarCaRE
T2 - rationale and design of the European BiomarCaRE project including 300,000 participants from 13 European countries
AU - Zeller, Tanja
AU - Hughes, Maria
AU - Tuovinen, Tarja
AU - Schillert, Arne
AU - Conrads-Frank, Annette
AU - Ruijter, Hester den
AU - Schnabel, Renate B
AU - Kee, Frank
AU - Salomaa, Veikko
AU - Siebert, Uwe
AU - Thorand, Barbara
AU - Ziegler, Andreas
AU - Breek, Heico
AU - Pasterkamp, Gerard
AU - Kuulasmaa, Kari
AU - Koenig, Wolfgang
AU - Blankenberg, Stefan
PY - 2014/10
Y1 - 2014/10
N2 - Biomarkers are considered as tools to enhance cardiovascular risk estimation. However, the value of biomarkers on risk estimation beyond European risk scores, their comparative impact among different European regions and their role towards personalised medicine remains uncertain. Biomarker for Cardiovascular Risk Assessment in Europe (BiomarCaRE) is an European collaborative research project with the primary objective to assess the value of established and emerging biomarkers for cardiovascular risk prediction. BiomarCaRE integrates clinical and epidemiological biomarker research and commercial enterprises throughout Europe to combine innovation in biomarker discovery for cardiovascular disease prediction with consecutive validation of biomarker effectiveness in large, well-defined primary and secondary prevention cohorts including over 300,000 participants from 13 European countries. Results from this study will contribute to improved cardiovascular risk prediction across different European populations. The present publication describes the rationale and design of the BiomarCaRE project.
AB - Biomarkers are considered as tools to enhance cardiovascular risk estimation. However, the value of biomarkers on risk estimation beyond European risk scores, their comparative impact among different European regions and their role towards personalised medicine remains uncertain. Biomarker for Cardiovascular Risk Assessment in Europe (BiomarCaRE) is an European collaborative research project with the primary objective to assess the value of established and emerging biomarkers for cardiovascular risk prediction. BiomarCaRE integrates clinical and epidemiological biomarker research and commercial enterprises throughout Europe to combine innovation in biomarker discovery for cardiovascular disease prediction with consecutive validation of biomarker effectiveness in large, well-defined primary and secondary prevention cohorts including over 300,000 participants from 13 European countries. Results from this study will contribute to improved cardiovascular risk prediction across different European populations. The present publication describes the rationale and design of the BiomarCaRE project.
KW - Adult
KW - Aged
KW - Biomarkers/blood
KW - Cardiovascular Diseases/blood
KW - Cooperative Behavior
KW - Databases, Factual
KW - European Continental Ancestry Group
KW - European Union
KW - Female
KW - Follow-Up Studies
KW - Humans
KW - International Cooperation
KW - Male
KW - MicroRNAs/blood
KW - Middle Aged
KW - Pilot Projects
KW - Population Surveillance/methods
KW - Prospective Studies
KW - Risk Factors
U2 - 10.1007/s10654-014-9952-x
DO - 10.1007/s10654-014-9952-x
M3 - SCORING: Journal article
C2 - 25238720
VL - 29
SP - 777
EP - 790
JO - EUR J EPIDEMIOL
JF - EUR J EPIDEMIOL
SN - 0393-2990
IS - 10
ER -